This webinar (jointly hosted by Together For Rare Diseases and ERICA, the European Rare Disease Research Coordination and Support consortium) aims to shed light on the unique and valuable contributions of the private sector in public private partnership efforts in research.
While PPPs are often perceived as a simple combination of private funding and academic knowledge, the reality is far more nuanced and impactful.
We will explore how pharmaceutical, and biotech companies bring more than just financial resources to the table. We will discuss their role in providing specialized expertise, cutting-edge technologies, and global infrastructure that can significantly accelerate rare disease research. From regulatory insights and operational capabilities to patient engagement strategies and data analytics, we will examine how industry partners complement academic strengths to create synergies that drive innovation. By understanding these contributions, we can foster more effective collaborations and ultimately improve outcomes for patients with rare diseases.
Main objectives:
- To articulate the contribution of industry in public private partnerships beyond funding
- To provide examples of concrete examples on how industry brought value to research projects
This webinar is part of a series. The first webinar will take place on 2 December 2024, focusing on ERNs: a key EU infrastructure to partner for research activities, the why and the when. A recording will be uploaded to our channels after the webinar takes place.
Follow us on LinkedIn for more updates and news.
Speakers:
- Anton Ussi, Operations and Finance Director, EATRIS
- Vinciane Pirard, Scientific Advocacy and Insights, Global Medical Affairs – Rare Diseases, Sanofi
- Dr Luca Sangiorgi, Director, Rare Bone Disorders Department and Coordinator Rare Bone Diseases Centre Istituto Ortopedico Rizzoli, ERN BOND Coordinator, ERN BOND
- Sheela Upadhyaya, Chair, Together 4 Rare Diseases